Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Glepaglutide in Healthy Subjects
NCT03279302Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glepaglutide in short bowel syndrome (SBS) (5 arms), sponsored by Zealand Pharma. Primary endpoints: Pharmacokinetic parameter - half life, Pharmacokinetic parameter - total body clearance and 3 more. Started Sep 2017; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03279302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279302.